Literature DB >> 32618599

Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.

Jia Qin1, Takaaki Higashi2, Shigeki Nakagawa2, Naoto Fujiwara3,4, Yo-Ichi Yamashita2, Toru Beppu2, Hideo Baba2, Masahiro Kobayashi5, Hiromitsu Kumada5, Ganesh Gunasekaran6, Thomas D Schiano7, Swan N Thung8, Maria Isabel Fiel8, Yujin Hoshida4, Stephen C Ward8.   

Abstract

Steatohepatitic hepatocellular carcinoma (SH-HCC) is a variant of hepatocellular carcinoma (HCC) with established association with nonalcoholic steatohepatitis (NASH), while its association with alcoholic steatohepatitis (ASH) is unclear. We studied 2 cohorts of patients who underwent resection for HCC in the setting of steatohepatitis. In our Mount Sinai (New York) cohort, we found SH-HCC in 17/24 (71%) patients with NASH and in 14/19 (74%) patients with ASH, while SH-HCC was the predominant tumor morphology in 12/24 (50%) in the NASH group and 9/19 (47%) in the ASH group. Upon review, 12/19 patients diagnosed with ASH also had diabetes and/or a body mass index >30. When these patients were removed, we still found similar rates of SH-HCC (6/7 [86%] showed SH-HCC, while SH-HCC was predominant in 3/7 [43%]. Interestingly, glycogenated hepatocyte nuclei were seen in the nontumor liver in 4/7 (57%) of these cases. In our Japan cohort, we also found similar rates of SH-HCC in NASH and ASH patients with HCC, 15/58 (26%), and 16/45 (36%), respectively. We determined molecular subclassification of tumors from the Japan cohort and found no difference in the distribution of S1, S2 and S3 subclasses among the ASH and NASH groups, though, among cases of SH-HCC, there was a trend toward an association of ASH with S1 (P=0.054) and NASH with S3 (P=0.052). Our study shows that SH-HCC is common in both ASH and NASH and that both underlying liver diseases produce tumors with similar molecular profiles, though different pathways may underlie the development of SH-HCC in ASH versus NASH.

Entities:  

Mesh:

Year:  2020        PMID: 32618599      PMCID: PMC7942811          DOI: 10.1097/PAS.0000000000001533

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  26 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Linda Henry; Chapy Venkatesan; Alita Mishra; Madeline Erario; Sharon Hunt
Journal:  Hepatology       Date:  2015-10-24       Impact factor: 17.425

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  The pathology of diabetic hepatitis.

Authors:  N Nagore; P J Scheuer
Journal:  J Pathol       Date:  1988-10       Impact factor: 7.996

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification.

Authors:  Poh Seng Tan; Shigeki Nakagawa; Nicolas Goossens; Anu Venkatesh; Tiangui Huang; Stephen C Ward; Xiaochen Sun; Won-Min Song; Anna Koh; Claudia Canasto-Chibuque; Manjeet Deshmukh; Venugopalan Nair; Milind Mahajan; Bin Zhang; Maria Isabel Fiel; Masahiro Kobayashi; Hiromitsu Kumada; Yujin Hoshida
Journal:  Liver Int       Date:  2015-06-29       Impact factor: 5.828

8.  Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.

Authors:  Javier De Luca-Johnson; Kirk J Wangensteen; Joshua Hanson; Edward Krawitt; Rebecca Wilcox
Journal:  Dig Dis Sci       Date:  2016-06-04       Impact factor: 3.199

9.  Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma.

Authors:  Jee San Lee; Jeong Eun Yoo; Haeryoung Kim; Hyungjin Rhee; Myoung Ju Koh; Ji Hae Nahm; Jin Sub Choi; Kee-Ho Lee; Young Nyun Park
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

Review 10.  Steatohepatitic Variant of Hepatocellular Carcinoma: A Focused Review.

Authors:  Andrea Morgan Olofson; David Hernandez Gonzalo; Michael Chang; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-12-17
View more
  1 in total

Review 1.  Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes.

Authors:  Michael S Torbenson
Journal:  Hum Pathol       Date:  2020-12-30       Impact factor: 3.526

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.